Agonistic anti-CD40 monoclonal antibodies (mAbs) are in clinical development based on the notion of directly activating APCs to stimulate immune responses either against intrinsic antigens, e.g., tumor-associated antigens (TAAs), or as an adjuvant to protein or peptide vaccines (2–4). This evidence concerns the gene CD40 and neoplasm.